# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announ...
Common Stock To Begin Trading On Nasdaq Capital Market Under Symbol ALGS With New CUSIP Number 01626L 204
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $...
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathwa...
Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (9...